Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting

March 28, 2023, 10:00 a.m. – 5:00 p.m. ET

Clara Barton Auditorium and we binar

Unite d States Patent and Trademark Office

10:00 – 10:10 a.m.	Welcome and opening remarks	Robin Evans, Deputy Commissioner for Patents
		Gladys Corcoran, Assistant Commissioner, USPTO
10:10 – 11:10 a.m.	Non-Statutory Double Patenting	Daniel Kolker, Supervisory Patent Examiner (SPE)
		Lora Driscoll, Technology Center Quality Assurance Specialist (TQAS) TC 1600
11:10 – 11:20 a.m.	Break	
11:20-12:10 p.m.	Non-Statutory Double Patenting	Daniel Kolker, Supervisory Patent Examiner (SPE)
		Lora Driscoll, Technology Center Quality Assurance Specialist (TQAS) TC 1600
12:10– 1:00 p.m.	Lunch	
1:00 – 1:45 p.m.	Declaration practice under 37 CFR 1.132	Gregory Emch, Supervisory Patent Examiner (SPE)
1:45-2:30 p.m.	Patent Term Extension (PTE) under 35 U.S.C. 156	Andrea Grossman, Legal Advisor Office of Patent Legal Administration (OPLA)



2:30-3:30 p.m.	Artificial intelligence in biotech/drug development	Michael Fuller, Managing Partner, Knobbe Martens
3:30-3:40 p.m.	Break	
3:40-4:10 p.m.	Cancer Moonshot Expedited Examination Pilot Program	Gary Nickol, Supervisory Patent Examiner (SPE) Brandon Fetterolf, Supervisory Patent Examiner (SPE)
4:10-4:50 p.m.	Common Mistakes ST.26	Christopher Babic, Director (acting) TC 1600, USPTO Mary Till, Senior Legal Advisor Office of Patent Legal Administration (OPLA)
4:50-5:00 p.m.	Closing remarks	Daniel Sullivan Director, TC1600, USPTO Gary Jones, Director TC 1600, USPTO Christopher Babic, Director (acting) TC 1600, USPTO

